Evidence map›Paper›PMID 35028545›Full record

ArticleEClinicalMedicine2022

Identifying and predicting severe bronchiolitis profiles at high risk for developing asthma: Analysis of three prospective cohorts.

Michimasa Fujiogi, Orianne Dumas, Kohei Hasegawa, Tuomas Jartti, Carlos A Camargo

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Patterns of Use of β-2 Agonists, Steroids, and Mucoactive Medications to Treat Bronchiolitis in the PICU: U.S. Pediatric Health Information System 2009-2022 Database Study.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Michimasa FujiogiDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, 125 Nashua Street, Suite 920, Boston, MA 02114-1101, USA.
Orianne DumasÉquipe d'Épidémiologie Respiratoire Intégrative, Université Paris-Saclay, UVSQ, Université Paris-Sud, Inserm, CESP, Villejuif 94807, France.
Kohei HasegawaDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, 125 Nashua Street, Suite 920, Boston, MA 02114-1101, USA.
Tuomas JarttiPEDEGO Research Unit, Medical Research Center, University of Oulu, Oulu, Finland.
Carlos A CamargoDepartment of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, 125 Nashua Street, Suite 920, Boston, MA 02114-1101, USA.
Harvard University · USUniversité Paris-Sud · FRUniversity of Turku · FI

Funding

Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUH3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARLOS ARTURO CAMARGO · 2018 to 2026
$12.1M
Host genetics, early-life microbiome, and childhood asthma: MARC-43 BostonUG3OD023253 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2016 to 2024
$6.8M
Prospective Cohort Study of Severe Bronchiolitis and Risk of Recurrent WheezingU01AI087881 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2011 to 2016
$6.2M
Airway dual-transcriptomics in bronchiolitis and risk of asthma: MARC-35 cohortR01AI137091 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.3M
Airway metagenome & metabolome in bronchiolitis and risk of asthma: MARC-35 cohortR01AI134940 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HASEGAWA, KOHEI · 2018 to 2022
$4.0M
NIAID NIH HHS R01 AI134940NIAID NIH HHS R01 AI137091NIAID NIH HHS U01 AI087881NIH HHS UG3 OD023253NIH HHS UH3 OD023253
6 · The paper itself

Abstract

backgroundBronchiolitis is the leading cause of infants hospitalization in the U.S. and Europe. Additionally, bronchiolitis is a major risk factor for the development of childhood asthma. Growing evidence suggests heterogeneity within bronchiolitis. We sought to identify distinct, reproducible bronchiolitis subgroups (profiles) and to develop a decision rule accurately predicting the profile at the highest risk for developing asthma.

methodsIn three multicenter prospective cohorts of infants (age < 12 months) hospitalized for bronchiolitis in the U.S. and Finland (combined

findingsWe identified four bronchiolitis profiles (profiles A-D). Profile A (

interpretationIn three prospective cohorts of infants with bronchiolitis, we identified clinically distinct profiles and their longitudinal relationship with asthma risk. We also derived and validated an accurate prediction rule to determine the profile at highest risk. The current results should advance research into the development of profile-specific preventive strategies for asthma.

Indexed as

asthmabronchiolitislatent class analysisphenotypespredictionvirus

Identifiers

PMID35028545
PMCPMC8741473
OpenAlexW4206076721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.